Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation
Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation
复制标题
DOI：
10.1016/j.leukres.2012.08.012
复制
发表时间：
2012-11-01
影响因子：
2.7
通讯作者：
Yokoyama, Akihito
中科院分区：
文献类型：
--
作者：
Ikezoe, Takayuki;Takeuchi, Asako;Yokoyama, Akihito
我们使用人可溶性血栓调节蛋白（rTM）联合全反式维甲酸（ATRA）和化疗治疗急性早幼粒细胞白血病（APL）引起的弥散性血管内凝血（DIC）患者（n = 9），并将临床结果与接受ATRA和/或化疗的历史对照患者（n = 8）进行比较。2例对照组患者发生颅内血管事件。另一方面，在rTM治疗的患者中未观察到出血相关死亡。值得注意的是，用rTM治疗比历史对照更早地将患者从DIC中拯救出来（对数秩检验，p = 0.019）。这些结果表明，应考虑使用rTM治疗与APL相关的DIC患者。(C)2012爱思唯尔有限公司保留所有权利。
We treated individuals for disseminated intravascular coagulation (DIC) caused by acute promyelocytic leukemia (APL) (n = 9) using human soluble thrombomodulin (rTM) in combination with all-trans retinoic acid (ATRA) and chemotherapy, and compared the clinical outcomes with historical control patients (n = 8) treated with ATRA and/or chemotherapy. Two control patients developed intracranial vascular incidents. On the other hand, no bleeding related mortality was noted in rTM-treated patients. Notably, treatment with rTM rescued patients from DIC earlier than historical controls (log rank test, p = 0.019). These results suggest that administration of rTM should be considered for the treatment of individuals with DIC associated with APL. (C) 2012 Elsevier Ltd. All rights reserved.